Mauna Kea looks to raise $67.7M in IPO

France's Mauna Kea Technologies, which makes the world's smallest microscope used to examine the inside of the human body, is hoping to raise about $67.7 million from its initial public offering. As Reuters notes, the company is moving ahead with its plans even though more than 15 European IPO deals have failed this year, including Agendia, a Dutch maker of breast cancer tests, and Verallia, Saint-Gobain's glass container unit. Mauna Kea, which is set to list on the NYSE Euronext, said the price range of its IPO would be between €10.65 and €13 a share and that the offer would close July 4. Story

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.